TY - JOUR
T1 - Uveitis for the non-ophthalmologist
AU - Burkholder, Bryn M.
AU - Jabs, Douglas A.
N1 - Funding Information:
Grant support: Supported in part by grant R01 EY026593 from the National Eye Institute, the National Institutes of Health, Bethesda, MD, US. Contributorship statement: Both DAJ and BMB performed the literature search, wrote the article, and participated in its revisions. DAJ is the guarantor.
Publisher Copyright:
© Publications
PY - 2021/2/3
Y1 - 2021/2/3
N2 - The uveitides are a heterogeneous group of diseases characterized by inflammation inside the eye. The uveitides are classified as infectious or non-infectious. The noninfectious uveitides, which are presumed to be immune mediated, can be further divided into those that are associated with a known systemic disease and those that are eye limited,-ie, not associated with a systemic disease. The ophthalmologist identifies the specific uveitic entity by medical history, clinical examination, and ocular imaging, as well as supplemental laboratory testing, if indicated. Treatment of the infectious uveitides is tailored to the particular infectious organism and may include regional and/or systemic medication. First line treatment for non-infectious uveitides is corticosteroids that can be administered topically, as regional injections or surgical implants, or systemically. Systemic immunosuppressive therapy is used in patients with severe disease who cannot tolerate corticosteroids, require chronic corticosteroids at >7.5 mg/day prednisone, or in whom the disease is known to respond better to immunosuppression. Management of many of these diseases is optimized by coordination between the ophthalmologist and rheumatologist or internist.
AB - The uveitides are a heterogeneous group of diseases characterized by inflammation inside the eye. The uveitides are classified as infectious or non-infectious. The noninfectious uveitides, which are presumed to be immune mediated, can be further divided into those that are associated with a known systemic disease and those that are eye limited,-ie, not associated with a systemic disease. The ophthalmologist identifies the specific uveitic entity by medical history, clinical examination, and ocular imaging, as well as supplemental laboratory testing, if indicated. Treatment of the infectious uveitides is tailored to the particular infectious organism and may include regional and/or systemic medication. First line treatment for non-infectious uveitides is corticosteroids that can be administered topically, as regional injections or surgical implants, or systemically. Systemic immunosuppressive therapy is used in patients with severe disease who cannot tolerate corticosteroids, require chronic corticosteroids at >7.5 mg/day prednisone, or in whom the disease is known to respond better to immunosuppression. Management of many of these diseases is optimized by coordination between the ophthalmologist and rheumatologist or internist.
UR - http://www.scopus.com/inward/record.url?scp=85100388453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100388453&partnerID=8YFLogxK
U2 - 10.1136/bmj.m4979
DO - 10.1136/bmj.m4979
M3 - Review article
C2 - 33536186
AN - SCOPUS:85100388453
VL - 372
JO - British Medical Journal
JF - British Medical Journal
SN - 0959-8146
M1 - m4979
ER -